We Can Always Learn More

Sign up here to join a community committed to taking action.

terms of service.

Terms of Service

By clicking "Sign Up," you certify that you are at least 18 years old and you are opting to receive communications including tips and tools, treatments options and other information from Progenics. You will be able to opt out of these communications at any time.

This consent will be in effect until such time as you opt out of communications from Progenics.

Please see our Privacy Policy for information about our practices regarding collection, use, and disclosure of information you provide us.

The information on this site is not intended to make a diagnosis or to take the place of talking to a US healthcare professional.

This site is intended solely for US residents and is governed solely by US laws and government regulations.

© 2019 Progenics Pharmaceuticals, Inc. All rights reserved

Progenics' trademarks, registered or otherwise, are the property of Progenics Pharmaceuticals, Inc. All content of this website, including text, images, graphics, sound files, and their arrangement, belongs to Progenics and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. Please see our Privacy Policy for additional information. While Progenics makes reasonable efforts to include accurate, up-to-date information on the site, Progenics makes no warranties or representations as to its accuracy.

References
  1. Kirmani S, Young W. 2014.
  2. Beard CM, et al. Mayo Clin Proc. 1983;58(12):802-804.
  3. Fishbein L. Hematol Oncol Clin North Am. 2016;30(1):135-150.
  4. Lenders JWM, et al. J Clin Endocrinol Metab. 2014; 99(6):1915–1942.
  5. Lefebvre M, Foulkes WD. Curr Oncol. 2014;21(1):e8-e17.
  6. Carrasquillo JA, et al. Semin Nucl Med. 2016;46(3):203-214.
  7. Yao JC, et al. J Clin Oncol. 2008;26(18):3063-3072.
  8. Martucci VL, Pacak K. Curr Probl Cancer. 2014;38(1):7-41.
  9. American Cancer Society. Cancer Facts & Figures 2017; 2017.
  10. American Cancer Society. Cancer Facts & Figures 2019; 2019.
  11. US Census Bureau. US and World Population Clock. https://www.census.gov/popclock/. Accessed April 1, 2019.
  12. Lam A. Endocr Pathol. 2017;1-15
  13. Gunawardane PTK, Grossman A. Adv Exp Med Biol. 2017;956:239-259.
  14. Ayala-Ramirez M, et al. J Clin Endocrinol Metab. 2011;96(3):717-725.
  15. Jimenez C, et al. Curr Oncol Rep. 2013;15(4):356-371.
  16. Eisenhofer G, et al. Endocr Relat Cancer. 2004;11:423-436.
  17. Scholz T, et al. J Clin Endocrinol Metab. 2007;92(4):1217-1225.
  18. Lloyd RV, et al. WHO Classification of Tumours of the Endocrine Organs. 4th ed. 2017.
  19. Amar L, et al. Horm Metab Res. 2012;44(5):385-389.
  20. Baudin E, et al. Eur J Endocrinol. 2014;171(3):R111-R1122.
  21. Erlic Z, Neumann HP. Hormones (Athens). 2009;8(1):29-38.
  22. Sandler MR, et al. Soc Med. 1967;60:(23-25):795-797.
  23. Engelman K. Bull N Y Acad Med. 1969;45(9):851-858.
  24. Phan A. Case-Based Discussion- Systemic Therapies for Advanced PHEO and PGL. In: European Society for Medical Oncology (ESMO) Congress 2014; September 26-30, 2014; Madrid, Spain.
  25. Zuber SM, et al. Endocrinol Metab Clin North Am. 2011;40(2):295-311.
  26. Gruber LM, et al. J Clin Endocrinol Metab. 2019;104(5):1386-1393.
  27. Young WF. Endocrine Hypertension. In: Melmed S, et al. Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: Elsevier; 2016.
  28. Barrett JA, et al. Cancer Biother Radiopharm. 2010;25(3):299-308.
  29. Saveanu A, et al. Endocr Relat Cancer. 2011;18(2):287-300.
  30. Ilias I, Pacak K. Nucl Med Biol. 2008;35 Suppl 1:S27-S34.
  31. Blanchet EM, et al. Front Oncol. 2012;1(58):1-9.
  32. Pandit-Taskar N, Modak S. J Nucl Med. 2017;58(9.2):39S-53S.
  33. Roman-Gonzalez A, Jimenez C. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):174-183.
  34. Jimenez C. Front Endocrinol. 2018;9(227):1-12.
  35. Park J, et al. Korean J Urol. 2011;52:241-246.
  36. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 7, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  37. Fishbein L, et al. Ann Surg Oncol. 2013;20(5):1444-1450.
  38. Asa SL, et al. J Clin Med. 2018;7(280):1-15.
  39. Brito JP, et al. Clin Endocrinol (Oxf). 2015;82(3):338-345.
  40. Eisenhofer G, et al. Clin Biochem Rev. 2017;38(2):69-100.

NP-US-AZ-0058